TNFSF11 and neoplasm: The authors concluded that two weeks of RANKL inhibition did not have an effect on the tumor proliferation rate but significantly increased the number of tumor infiltrating lymphocytes (TILs) in the tumor environment, making them theoretically more susceptible for immune therapy.